Extend Biosciences

Executive Summary

Extend Biosciences is a privately held biotechnology company leveraging its proprietary drug delivery platform to develop long-acting therapeutics for metabolic and endocrine disorders. By extending the half-life of peptides and proteins, the technology enables less frequent dosing and improved patient outcomes. The company's lead candidate is a long-acting parathyroid hormone (PTH) analog for hypoparathyroidism, a condition with limited treatment options. Founded in 2009 and based in Cambridge, MA, Extend Biosciences has not disclosed its total funding or valuation, suggesting it remains in early to mid-stage development. The company's platform has broad applicability across multiple therapeutic areas, potentially reducing injection frequency and enhancing efficacy for chronic diseases. With an aging population and increasing prevalence of metabolic disorders, Extend's technology addresses a significant unmet need. However, the lack of public clinical data and financial transparency introduces uncertainty. The company's success depends on advancing its PTH program through clinical trials and securing partnerships or financing to support development. Given the early stage, the conviction score is moderate, reflecting potential but limited near-term visibility.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 1 Clinical Trial for Long-Acting PTH Analog70% success
• H1 2027Series B or C Funding Round60% success
• H2 2027FDA Pre-IND Meeting for Second Indication50% success